ArticleFrontiers in aging neuroscience2026
Rethinking cervical deep lymphovenous anastomosis in Alzheimer's disease: problems and prospects.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep cervical lymphovenous reconstruction in Alzheimer's disease: three target-defined interfaces with distinct mechanistic implications.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deep cervical lymphovenous anastomosis (DCLVA) has been proposed as a novel surgical strategy to promote brain waste clearance in Alzheimer's disease (AD), inspired by advances in glymphatic and meningeal lymphatic research. Early reports suggested possible cognitive benefits, yet the scientific basis of this approach remains controversial. Discussion: This Perspective critically examines the mechanistic rationale, anatomical limitations, and methodological shortcomings underlying DCLVA. The pressure disparity between cervical lymphatic and venous systems challenges the physiological feasibility of the procedure, while existing studies lack randomized design, biomarker validation, and control for anesthesia-related confounding. Ethical and translational considerations further underscore the need for rigorous preclinical and clinical evaluation before any clinical adoption. Summary: While DCLVA reflects an innovative attempt to translate lymphatic biology into surgical therapy, its current theoretical and empirical foundation is insufficient. A shift toward mechanistic validation, objective imaging biomarkers, and non-invasive modulation of lymphatic function is warranted before DCLVA can be considered a viable therapeutic option for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.